ScinoPharm Taiwan Ltd (TWSE:1789), a process R&D and API manufacturing service provider to the global pharmaceutical industry, announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS).
According to ScinoPharm Taiwan, it is the only pharmaceutical company in Taiwan to achieve this milestone.
The company says that it is actively progressing regulatory submissions and forging collaborations across Europe, Asia, and emerging markets to expand its international presence in the generic drug product market and build on its already strong position on the generic API front.
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic